APOE genotype and early β-amyloid accumulation in older adults without dementia

Neurology

Volumn 89, Issue 10, 2017, Pages 1028-1034

  Lim, Yen Ying ^a   Mormino, Elizabeth C ^b  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b STANFORD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; APOLIPOPROTEIN E2; APOLIPOPROTEIN E3; APOLIPOPROTEIN E4; FLORBETAPIR; TRACER; UNCLASSIFIED DRUG; ANILINE DERIVATIVE; ETHYLENE GLYCOL DERIVATIVE; RADIOPHARMACEUTICAL AGENT;

AGE; AGED; ALLELE; ARTICLE; BRAIN TOMOGRAPHY; COMPARATIVE STUDY; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; FEMALE; FOLLOW UP; GENETIC ASSOCIATION; GENOTYPE; HETEROZYGOTE; HIGH RISK POPULATION; HOMOZYGOTE; HUMAN; MAJOR CLINICAL STUDY; MALE; MILD COGNITIVE IMPAIRMENT; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; AGING; BRAIN; DIAGNOSTIC IMAGING; GENETICS; METABOLISM; RISK FACTOR; STATISTICAL MODEL; SUPERIOR SAGITTAL SINUS;

AGED; AGING; AMYLOID BETA-PEPTIDES; ANILINE COMPOUNDS; APOLIPOPROTEIN E2; APOLIPOPROTEIN E3; APOLIPOPROTEIN E4; BRAIN; CROSS-SECTIONAL STUDIES; ETHYLENE GLYCOLS; FEMALE; HETEROZYGOTE; HUMANS; LINEAR MODELS; MALE; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; RISK FACTORS; SUPERIOR SAGITTAL SINUS;

EID: 85028801487     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0000000000004336     Document Type: Article

References (29)

1. Jack CR, Wiste HJ, Weigand SD, et al. Age, sex, and APOE e4 effects on memory, brain structure, and b-amyloid across the adult life span. JAMA Neurol 2015;72: 511-519.
2. Sperling RA, Rentz DM, Johnson KA, et al. The A4 study: Stopping AD before symptoms begin? Sci Translational Med 2014;6:228-213.
3. Reiman EM, Langbaum JB, Fleisher AS, et al. Alzheimer's Prevention Initiative: A plan to accelerate the evaluation of presymptomatic treatments. J Alzheimer's Dis 2011;26: 321-329.
4. Mills SM, Mallmann J, Santacruz AM, et al. Preclinical trials in autosomal dominant AD: Implementation of the DIAN-TU trial. Revue Neurologique 2013;169:737-743.
5. Liu CC, Kanekiyo T, Xu H, Bu G. Apolipoprotein E and Alzheimer disease: Risk, mechanisms and therapy. Nat Rev Neurol 2013;9:106-118.
6. Bilgel M, An Y, Zhou Y, et al. Individual estimates of age at detectable amyloid onset for risk factor assessment. Alzheimer's Demen 2016;12:373-379.
7. Ossenkoppele R, Jansen WJ, Rabinovici GD, et al. Prevalence of amyloid PET positivity in dementia syndromes: A meta-analysis. J Am Med Assoc 2015;313:1939-1949.
8. Resnick SM, Bilgel M, Moghekar A, et al. Changes in Ab biomarkers and associations with APOE genotype in 2 longitudinal cohorts. Neurobiol Aging 2015;36:2333-2339.
9. Villemagne VL, Burnham S, Bourgeat P, et al. Amyloid b deposition, neurodegeneration and cognitive decline in sporadic Alzheimer's disease: A prospective cohort study. Lancet Neurol 2013;12:357-367.
10. Rowe CC, Ellis KA, Rimajova M, et al. Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging. Neurobiol Aging 2010;31: 1275-1283.
11. Ashford JW. APOE genotype effects on Alzheimer's disease: Onset and epidemiology. J Mol Neurosci 2004;23: 157-165.
12. GrotheMJ, Villeneuve S, DyrbaM, Bartrés-Faz D, WirthM; Alzheimer's Disease Neuroimaging Initiative. Multimodal characterization of older APOE2 carriers reveals selective reduction of amyloid load. Neurology 2017;88:569-576.
13. Toledo JB, Zetterberg H, van Harten AC, et al. Alzheimer's disease cerebrospinal fluid biomarker in cognitively normal subjects. Brain 2015;138:2701-2715.
14. Bangen KJ, Clark AL, Werhane M, et al. Cortical amyloid burden differences across empirically-derived mild cognitive impairment subtypes and interaction with APOE e4 genotype. J Alzheimer's Dis 2016;52:849-861.
15. Petersen RC, Aisen PS, Beckett LA, et al. Alzheimer's Disease Neuroimaging Initiative (ADNI): Clinical characterization. Neurology 2010;74:201-209.
16. Landau SM, Mintun MA, Joshi AD, et al. Amyloid deposition, hypometabolism, and longitudinal cognitive decline. Ann Neurol 2012;72:578-586.
17. Mormino EC, Betensky RA, Hedden T, et al. Amyloid and APOE E4 interact to influence short-term decline in preclinical Alzheimer's disease. Neurology 2014;82:1760-1767.
18. Landau SM, Fero A, Baker SL, et al. Measurement of longitudinal b-amyloid change with 18F-florbetapir PET and standardized uptake value ratios. J Nucl Med 2015; 56:567-574.
19. Chen K, Roontiva A, Thiyyagura P, et al. Improved power for characterizing longitudinal amyloid-b PET changes and evaluating amyloid-modifying treatments with a cerebral white matter reference region. J Nucl Med 2015;56: 560-566.
20. Landau SM, Breault C, Joshi AD, et al. Amyloid-b imaging with Pittsburgh compound B and florbetapir: Comparing radiotracers and quantification methods. J Nucl Med 2013;54:70-77.
21. Wolf AB, Valla J, Bu G, et al. Apolipoprotein E as a Bamyloid independent factor in Alzheimer's disease. Alzheimer's Res Ther 2013;5:38.
22. Vlassenko AG, Mintun MA, Xiong C, et al. Amyloid-beta plaque growth in cognitively normal adults: Longitudinal [11C]Pittsburgh compound B data. Ann Neurol 2011;70: 857-861.
23. Reiman EM, Langbaum JB, Tariot PN. Alzheimer's Prevention Initiative: A proposal to evaluate presymptomatic treatments as quickly as possible. Biomarkers Med 2010;4: 3-14.
24. Sperling RA, Jack CR, Aisen PS. Testing the right target and right drug at the right stage. Sci Translational Med 2011;3:111-133.
25. Yan R, Vassar R. Targeting the b secretase BACE1 for Alzheimer's disease therapy. Lancet Neurol 2014;13: 319-329.
26. Hyman BT, Gomez-Isla T, Rebeck GW, et al. Epidemiological, clinical, and neuropathological study of Apolipoprotein E genotype in Alzheimer's disease. Ann NY Acad Sci 2006;802:1-5.
27. Jack CR, Wiste HJ, Weigand SD, et al. Amyloid-first and neurodegeneration-first profiles characterize incident amyloid PET positivity. Neurology 2013;81:1732-1740.
28. Guo T, Brendel M, Grimmer T, Rominger A, Yakushev I. Baseline amyloid PET predicts spatial pattern of betaamyloid accumulation over time. J Nucl Med 2016;57: 510.
29. Rodrigue KM, Rieck JR, Kennedy KM, Devous MDS, Diaz-Arrastia R, Park DC. Risk factors for b-amyloid deposition in healthy aging: Vascular and genetic effects. JAMA Neurol 2013;70:600-606.